BAP1 and intrahepatic cholangiocarcinoma: The last group was enriched for individuals with a diagnosis of perihilar cholangiocarcinoma (PHCC) and GBC (n = 38; 79.2%), whereas patients with intrahepatic cholangiocarcinoma (ICC) were more likely to harbor IDH1-2/BAP1/PBRM1 mutations (n = 14; 60.9%).